Autres langues Lifeward Ltd.

Actions

LFWD

IL0011331076

Equipement, fournitures et distribution médicale

Temps réel estimé Cboe BZX Autres places de cotation 20:27:29 25/06/2026			Varia. 5j.	Varia. 1 janv.
6,900 ^USD	-0,58%		-0,58%	-0,71%

19/05	Lifeward Ltd. nomme le Dr Keith D. Rose au poste de Chief Medical Officer	CI
15/05	Transcript : Lifeward Ltd., Q1 2026 Earnings Call, May 15, 2026

Autres langues

19/05	Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform
19/05	Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform
19/05	Lifeward Ltd. Appoints Dr. Keith D. Rose as Chief Medical Officer
15/05	Lifeward Reports First Quarter 2026 Financial Results
15/05	Lifeward Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026
11/05	Lifeward to Report First Quarter 2026 Financial Results on May 15, 2026
04/05	Lifeward Announces New ReWalk® Data Presented at ASIA 2026 Conference Demonstrating a Comprehensive Longitudinal Safety Analysis for a Powered Exoskeleton
04/05	Lifeward Announces New ReWalk® Data Presented at ASIA 2026 Conference Demonstrating a Comprehensive Longitudinal Safety Analysis for a Powered Exoskeleton
04/05	Lifeward Ltd Announces New Rewalk Data Presented At Asia 2026 Conference Demonstrating A Comprehensive Longitudinal Safety Analysis for A Powered Exoskeleton
25/03	Lifeward Closes Oramed Partnership, Acquires Oratech Pharma
25/03	Lifeward Ltd. Announces Board and Committee Changes, Effective as of March 25, 2026
25/03	Lifeward Successfully Closes on Strategic Partnership with Oramed
25/03	Lifeward Ltd. announced that it has received $9 million in funding from Oramed Pharmaceuticals Inc.
25/03	Lifeward Ltd. completed the acquisition of Oratech Pharma, Inc. from Oramed Pharmaceuticals Inc..
18/03	Lifeward Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
18/03	Lifeward Reports Fourth Quarter and Full Year 2025 Financial Results
18/03	Lifeward Ltd. Auditor Raises 'Going Concern' Doubt
13/03	Lifeward Shareholders Approve Share Issuance for Oramed Partnership
13/03	Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company
13/03	Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company
11/03	Lifeward Regains Compliance with Nasdaq Minimum Bid Price Requirement
10/03	Lifeward to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
02/03	Lifeward Announces Collaboration With Shirley Ryan AbilityLab to Expand Access for the ReWalk Personal Exoskeleton
02/03	Lifeward Ltd. Announces Collaboration with Shirley Ryan AbilityLab to Expand Access for the ReWalk Personal Exoskeleton
27/02	Lifeward Ltd. Announces Departure of Hadar Levy as Class I Director of the Board of Directors, Effective February 24, 2026